Shares in Generex Biotechnology (OTC: GNBT) have not been able to rally since their January run when the penny stock hit $0.277. We profiled GNBT as one of our penny stock picks profiled in our newsletter when shares were just $0.1575 securing a 75% gain bottom-to-top. GNBT closed with a slight gain of 0.39% at $0.13 in the last trading session.
Generex seemed to be on the fast track at the start of 2012 to breakout with its search for a cure to breast cancer. The company’s Antigen Express AE37 has received an enormous amount of attention in the U.S. and Japan for its ability to prevent the recurrence of breast cancer in treated patients. If your investing in penny stocks with a long-term view to them, add GNBT to your list of penny stocks to watch.
Looking for Cheap Stocks? Subscribe and get our next penny stock picks FREE.
GNBT Stock Snap Shot:
Market Cap: 45.02M
(Jan 17, 2012): 0.277
(Dec 8, 2011): 0.076
Avg Vol (3 month): 1,542,190
Avg Vol (10 day): 374,143
Shares Outstanding: 346.30M
% Held by Insiders: 1.47%
Generex Technology’s wholly-owned subsidiary, Antigen, concentrates on developing proprietary vaccine formulations that work by stimulating the immune system to either attack offending agents (i.e., cancer cells, bacteria, and viruses) or to stop attacking benign elements (i.e., self proteins and allergens). Their immunomedicine products are based on two platform technologies and are in the early stages of development.
Bottom Line: GNBT just filed for the resale of 110,934,409 shares of their penny stock. Considering what prices the attached warrants are executable at, GNBT is one of those cheap stocks that are worth looking at long understanding that the stock price hasn’t been above $1 since Q1 of 2010.
Generex had a disappointing 2011 having reported just $292 thousand in revenues compared to $1.173 million in 2010. They also report that they have current obligations of $4,423,519 due before Jan. 31, 2013. If you work around some of these numbers and do some due diligence, this oncology focused penny stock could be a winner in a year or so.Share